- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04942574
Voice Biomarkers to Predict Excessive Daytime Sleepiness (SOMVOICE)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Excessive Daytime Sleepiness (EDS) is a frequent symptom that concerns between 5% and 8% of the population. The individual consequence of EDS is a diminution of the life quality. Furthermore, EDS is a cause of high socio-medical costs though the accidental risks that it induces at work and on the road (Ohayon, Reynolds et al. 2013). Indeed, it is a severe symptom due to the consequences that it is the cause of. Furthermore, EDS is associated to 5 to 20% of road accidents depending on the type of road network. As a consequence, to elaborate a sleepiness detection through voice in real time system is a major challenge for public health-care and medicine. Moreover, it offers benefits from a socio-medical aspect, as detecting sleepiness through voice doesn't require neither consumables furniture nor specialized staff to be set up.
To highlight the effect of sleepiness over voice, investigators designed this experiment around a night of total sleep deprivation. To measure objective sleepiness of subjects, they takes a MSLT test the day after a night of total sleep deprivation (or a supervised night for control). The complementary measures (KSS, VAS-A, VAS-F and Psychomotor Vigilance Task (PVT)) will allow to study the exact origin of the variations of the vocal markers induced by the sleep deprivation.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Pierre PHILIP, Pr
- Phone Number: +33 05 57 82 01 72
- Email: pierre.philip@u-bordeaux.fr
Study Contact Backup
- Name: Cécile Klochendler
- Phone Number: +33 05 57 82 01 82
Study Locations
-
-
-
Bordeaux, France
- Recruiting
- CHU de Bordeaux
-
Contact:
- Pierre PHILIP, Pr
- Phone Number: +33 0557820182
- Email: pierre.philip@u-bordeaux.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male ou female volunteers, who are between 18 and 50 years old,
- With a BMI (Body Mass Index) between 18.5 and 25 kg/m2 for volunteers who are between 18 and 34 years old, or a BMI between 18.5 and 27 kg/m2 for volunteers who are between 35 and 50 years old ,
- Not having subjective EDS (Excessive Daytime Sleepiness) : total score at ESS (Epworth Sleepiness Scale) lower or equal to 11,
- Not having insomnia complaints (ISI total score lower than 8),
- Having a SCL90R (Symptom Check List- 90 items Revised) score lower than 60 (only for Anxiety and Depression categories' items of the checklist),
- Regular bedtime between 22H00 and 0H00, regular get up time between 6H00 and 8H00,
- Daily TST (Total Sleep Time) between 7 and 9 hours,
- With no strong suspicion of OSAS (Obstructive Sleep Apnea Syndrome) as assessed by STOP-BANG questionnaire,
- With no suspicion of RLS (Restless Legs Syndrome) as assessed by RLS screening questionnaire,
- With sufficient reading abilities for the reading task as assessed by ECLA16+ ("Evaluation des Compétences de Lecture chez l'Adulte de plus de 16 ans" :
higher ou equal performances than 25th percentile for performances assessed in total population for the following tasks : " lecture de " l'Alouette " " (Number of correctly read words / minute ≥ 121, number of errors ≤ 10), isolated words reading (regular words : score ≥ 18, time ≤ 17 sec ; irregular words : score ≥ 16, time ≤ 16 sec, pseudo-words : score ≥ 17, time ≤ 26 sec), repetition of non-words (score ≥ 19), and symbol crossing task (number of crossed symbols ≥ 22),
- With a SE (Sleep Efficiency) higher or equal to 85% as assessed by the 7 nights-actigraphy made before inclusion,
- With an AHI (Apnea/Hypopnea Index) lower or equal to 10 apnea or hypopnea/hour of sleep as assessed by the ventilatory polygraphy,
- With a PLMI (Periodic Limb Movement Index) lower or equal to 15 sequences of PLM/hour of sleep as assessed by the ventilatory polygraphy,
- Being an affiliated member of the Social Security system,
- Being able to understand the study,
- Being available to come at the four visits necessary for the study,
- Having given written informed consent to participate to the study.
Exclusion Criteria:
- Having a life-threatening disease,
- Any evolutive cardiovascular pathology - under treatment or not,
- Any evolutive neurologic pathology - under treatment or not (brain tumour, epilepsy, headache, stroke, sclerosis, myoclonia, chorea, neuropathy, muscular dystrophies, myotonic dystrophy),
- Psychiatric disorders - under treatment or not (characterised depressive episode, bipolar disorders, psychotic disorders, neurodevelopmental diseases),
- Untreated endocrine disorders (diabetes, hyperthyroidism),
- Dependency to a substance,
- otorhinolaryngological disorder that could induce vocal parameters modification,
- Fluence disorders (cluttering, stuttering), language disorders (dyslexia) or visual troubles that could impact reading abilities,
- Participant under psychotropic treatment (antidepressants, antihistamine, etc…), or under treatment that could interfere with sleep or wakefulness level,
- Participant under treatment that could impact the normal muscular function (myorelaxant, neuromuscular blocking agents injections in maxillofacial area, etc…),
- Dental care during the follow-up of the study,
- Shift-worker or night-worker,
- Excessive consumption of alcohol (>2 glasses per day) during the 6 last months,
- Excessive consumption of coffee, tea, or any drink containing caffeine (like cola) (> 5 cups/day),
- Excessive tobacco smoking (>5 cigarets/day),
- Non-native French speaker,
- Participant with a thick accent that could induce significantly vocal parameters modification (at the discretion of the investigator),
- Deprived of liberty by a legal or administrative procedure,
- Under tutorship or guardianship,
- Pregnant or breastfeeding woman.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: First experimental visit : Total Sleep Deprivation
The participants enrolled in this arm will have a total sleep deprivation on their first experimental visit and a normal sleep on their second experimental visit.
|
Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.
Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.
|
|
Experimental: First experimental visit : Normal Sleep
The participants enrolled in this arm will have a normal on their first experimental visit and a total sleep deprivation sleep on their second experimental visit.
|
Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of total sleep deprivation.
Participants will perform repeatedly : task of reading with voice acquisition before each MSLT, KSS, VAS-Anxiety, VAS-Fatigue and PVT during the day after a night of normal sleep.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Acoustic fingerprint
Time Frame: Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
Acoustic fingerprint (statistics on prosody, frequency and energy) influenced by sleep deprivation measured at each iteration of TILE at visits V2 and V3.
|
Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
sleep onset
Time Frame: Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
The sleep onset at each iteration of the MSLT (in minutes).
This evaluate the objective sleepiness of the subject, right after that its voice has been recorded, allowing to link vocal markers and objective sleepiness of the subject.
|
Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
|
Karoslinska Sleepiness Scale questionnaire
Time Frame: Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
The score to the Karoslinska Sleepiness Scale questionnaire. This measure links the vocal markers with subjective instantaneous sleepiness. Minimum value 1 (extremely alert); maximum value 9 (extremely sleepy, fighting sleep) |
Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
|
VAS-Fatigue
Time Frame: Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
The score to the VAS-Fatigue. This measure links the vocal markers and with the fatigue of the subject. Visual analog scale from minimum (energetic, no fatigue) to maximum (worst fatigue possible) |
Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
|
VAS-Anxiety.
Time Frame: Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
The score to the VAS-Anxiety. This measure links the vocal markers and the anxiety level of the subject. Visual analog scale from minimum (calm) to maximum (anxious) |
Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
|
PVT
Time Frame: Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
The score to the PVT .
This links the vocal markers of the subject to its level of performance.
|
Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
|
lexical decision
Time Frame: Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
The scores to the lexical decision task
|
Visit (V2) between 7 and 10 days after inclusion (V1) and Visit 3 (V3) between 14 and 60 days after inclusion (V1)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHUBX 2020/57
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sleep Deprivation
-
University of PennsylvaniaCompletedSleep Restriction Then Total Sleep Deprivation | Total Sleep Deprivation Then Sleep RestrictionUnited States
-
Herlev HospitalTRYG Foundation; Danish Medical AssociationCompletedEffect of Sleep DeprivationDenmark
-
Christian BaumannCompletedAcute and Partial Sleep DeprivationSwitzerland
-
Laval UniversityCanadian Institutes of Health Research (CIHR)CompletedControl Condition | Intensive Sleep Retraining | Total Sleep DeprivationCanada
-
Dr. Osman HospitalCairo UniversityUnknownEffect of Insomnia and Sleep Deprivation in 3rdtrimesterEgypt
-
Hallym University Medical CenterCompletedWe Investigated the Effect of Sleep Deprivation on the Tear Film and Ocular Surface.Korea, Republic of
-
Emily GusemanCompleted
-
University of ChicagoCompleted
-
Beth Israel Deaconess Medical CenterNational Institute of Mental Health (NIMH)Active, not recruiting
Clinical Trials on Total sleep deprivation
-
Centre Hospitalier Universitaire de Saint EtienneJean Monnet UniversityRecruiting
-
Federal University of São PauloCompleted
-
IRCCS San RaffaeleRecruitingMood Disorders | Sleep Deprivation | Major Depressive DisorderItaly
-
Laval UniversityCanadian Institutes of Health Research (CIHR)CompletedControl Condition | Intensive Sleep Retraining | Total Sleep DeprivationCanada
-
Institut de Recherche Biomedicale des ArmeesCompleted
-
University of FloridaCompleted
-
Columbia UniversityNew York UniversityCompletedObesity | Sleep DeprivationUnited States
-
University of PittsburghCompleted